Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Abstract</jats:title><jats:p>Sequencing studies of Diffuse Large B Cell Lymphoma (DLBCL) have identified hundreds of recurrently altered genes. However, it remains largely unknown whether and how these mutations may contribute to lymphomagenesis, either individually or in combination. Existing strategies to address this problem predominantly utilize cell lines, which are limited by their initial characteristics and subsequent adaptions to prolonged<jats:italic>in vitro</jats:italic>culture. Here, we describe a novel co-culture system that enables the<jats:italic>ex vivo</jats:italic>expansion and viral transduction of primary human germinal center B cells. The incorporation of CRISPR/Cas9 technology enables high-throughput functional interrogation of genes recurrently mutated in DLBCL. Using a backbone of<jats:italic>BCL2</jats:italic>with either<jats:italic>BCL6</jats:italic>or<jats:italic>MYC</jats:italic>we have identified co-operating oncogenes that promote growth and survival, or even full transformation into synthetically engineered models of DLBCL. The resulting tumors can be expanded and sequentially transplanted<jats:italic>in vivo</jats:italic>, providing a scalable platform to test putative cancer genes and for the creation of mutation-directed, bespoke lymphoma models.</jats:p>

Original publication

DOI

10.1101/618835

Type

Journal article

Publisher

Cold Spring Harbor Laboratory

Publication Date

27/04/2019